Dr. Glenn Meyer is a seasoned pharmaceutical executive with over 32 years of professional experience in the industry. In 2012, he founded Live Oak Pharmaceuticals, Inc., a company dedicated to providing comprehensive development services, product profile development, and support for pharmaceutical product development across all dosage forms, routes of administration, and associated medical devices. Under his leadership, Live Oak Pharmaceuticals has become a trusted partner for companies seeking to optimize their product development processes.

Dr. Meyer’s career began at Abbott Laboratories in 1989, following his completion of a B.S. in Pharmacy from Albany College of Pharmacy and a Ph.D. in Pharmaceutical Chemistry from the University of Connecticut. At Abbott, he participated in an extensive pharmaceutical professional development program, gaining a deep understanding of all aspects of pharmaceutical development. His expertise led him to the CDMO sector in 1995, where he joined Applied Analytica, Inc. (AAI) in a managerial role. Over the years, he held multiple positions at AAI, culminating in responsibility for all internal sponsored research and serving on management teams for a joint venture with Tanabe-Seiyaku and a Collaborative License Agreement with Osmotica Pharmaceuticals.
In 2001, Dr. Meyer became the U.S. founding employee and Chief Operating Officer at Osmotica Pharmaceuticals, Inc. His strategic vision and leadership were instrumental in growing the company from its inception to a thriving enterprise with over $100 million in annual revenue and more than 250 employees. As Chief Scientific Officer, he spearheaded the development of a robust pipeline of neuroscience candidates targeting conditions such as muscle spasticity, depression, and Parkinson’s Disease.

Since launching Live Oak Pharmaceuticals, Dr. Meyer has continued to drive innovation in the pharmaceutical industry. He assists companies in developing products that not only meet the required profiles but also achieve optimal dosage forms that align with clinical endpoints, stability, bioavailability, and desired product performance characteristics. With over 25 patents to his name and numerous publications, Dr. Meyer remains at the forefront of pharmaceutical science, continually expanding the boundaries of knowledge through his product development efforts.